PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Paul, Carle
TI  - ESTEEM 2: Apremilast Significantly Reduced Psoriasis Severity Throughout 16 Weeks
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 15--16
VI  - 14
IP  - 37
4099  - http://mdc.sagepub.com/content/14/37/15.short
4100  - http://mdc.sagepub.com/content/14/37/15.full
AB  - Apremilast, an oral phosphodiesterase 4 inhibitor that works intracellularly to regulate inflammatory mediators, has been tested in the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) program, which consists of 2 trials: ESTEEM 1 [NCT01194219] and ESTEEM 2 [NCT01232283]. This article presents the 52-week results of the ESTEEM 2 trial.